US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

InflaRx NV (IFRX)

2.05

-0.01

(-0.49%)

終了 7月11日 5:00AM

2.02

-0.03

( -1.46% )

プレマーケット: 8:34PM

個人投資家向けのプロ仕様のツール。

プレミアム

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares

Jena, Germany, May 08, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Biotech Surges as Big Money Backs High-Stakes Kidney Disease Push

The immune system has become one of biotech's most important battlegrounds as drug developers race to target inflammatory pathways responsible for...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares

Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a...

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

InflaRx intends to develop izicopan in ANCA-associated vasculitis (AAV), with a secondary goal of establishing...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

JENA, Germany, May 04, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company...

InflaRx to Report First Quarter 2026 Results on May 7, 2026

JENA, Germany, May 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company...

glenn1919

glenn1919 3月前

IFRX.........................https://stockcharts.com/sc3/ui/?s=IFRX&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 8月前

IFRX......................................https://stockcharts.com/sc3/ui/?s=IFRX&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 8月前

IFRX...........................................https://stockcharts.com/sc3/ui/?s=IFRX&p=W&b=5&g=0&id=p86431144783

PinkPennies

PinkPennies 8月前

IFRX InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)
https://investorshub.advfn.com/stock-market/NASDAQ/inflarx-nv-IFRX/stock-news/97194845/inflarx-reports-positive-phase-2a-data-for-inf904

PinkPennies

PinkPennies 8月前

IFRX news .. InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria https://finance.yahoo.com/news/inflarx-announce-topline-data-phase-210500490.html

glenn1919

glenn1919 10月前

IFRX...........................................................https://stockcharts.com/h-sc/ui?s=IFRX&p=W&b=5&g=0&id=p86431144783

0210

11 yrs. I-hub absence, how's C3P0?...kewl IFRx DD, lol. 😉😂🤣

Monksdream

Monksdream 1年前

glenn1919

glenn1919 1年前

IFRX...............................................https://stockcharts.com/h-sc/ui?s=IFRX&p=W&b=5&g=0&id=p86431144783

RTWODTWO

RTWODTWO 1年前

InflaRx is entering a critical phase with several upcoming catalysts:

Phase 3 interim results for vilobelimab in Pyoderma Gangrenosum (PG) are expected shortly. The program already has both Fast Track and Orphan Drug Designation from the FDA, which could enable accelerated approval if the data are strong.

Phase 2a results for INF904 in Hidradenitis Suppurativa (HS) and Chronic Spontaneous Urticaria (CSU) are anticipated this summer. Both indications target large unmet medical needs and multi-billion-dollar markets.

Preclinical data for INF904 showed superior efficacy compared to Avacopan, which was acquired by Amgen for $3.7B.

InflaRx maintains a cash position of approximately $70M, suggesting the company is fully funded through these major milestones.

Guggenheim Securities has issued a $10 price target for IFRX, representing significant upside potential from current levels.

With multiple important readouts expected this year, IFRX could attract substantial attention if results are positive.

DYOR (Do Your Own Research)

Monksdream

Monksdream 1年前

Monksdream

Monksdream 1年前

glenn1919

glenn1919 2年前

ifrx...................................https://stockcharts.com/h-sc/ui?s=ifrx&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 2年前

IFRX.................................https://stockcharts.com/h-sc/ui?s=IFRX&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 2年前

IFRX..............................https://stockcharts.com/h-sc/ui?s=IFRX&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 2年前

IFRX.........................https://stockcharts.com/h-sc/ui?s=IFRX&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 2年前

IFRX.............................https://stockcharts.com/h-sc/ui?s=IFRX&p=W&b=5&g=0&id=p86431144783

glenn1919

glenn1919 2年前

IFRX....................https://stockcharts.com/h-sc/ui?s=IFRX&p=W&b=5&g=0&id=p86431144783

ralfito

ralfito 2年前

Is it just the strong financial reports or is there some other news you know of?
Thanks!

TrendTrade2016

TrendTrade2016 2年前

IFRX READY TO RUMBLE IN THE JUNGLE 2.9 TOP OF WEEKLY PLAY

glenn1919

glenn1919 2年前

IFRX.............................................https://stockcharts.com/h-sc/ui?s=IFRX&p=W&b=5&g=0&id=p86431144783

ralfito

ralfito 2年前

anyone know why its launching?

TrendTrade2016

TrendTrade2016 2年前

IFRX TAKING OFF

glenn1919

glenn1919 2年前

IFRX.......................https://stockcharts.com/h-sc/ui?s=IFRX&p=W&b=5&g=0&id=p86431144783

Monksdream

Monksdream 2年前

IFRX 10Q due AUGUST5

Monksdream

Monksdream 2年前

Monksdream

Monksdream 2年前

glenn1919

glenn1919 2年前

IFRX..................................https://stockcharts.com/h-sc/ui?s=IFRX&p=W&b=5&g=0&id=p86431144783

ralfito

ralfito 2年前

What is up with IFRX? Seems to be teetering. Numbers look good, except for Forward EPS.

glenn1919

glenn1919 2年前

IFRX...............................................https://stockcharts.com/h-sc/ui?s=IFRX&p=W&b=5&g=0&id=p86431144783

Monksdream

Monksdream 2年前

Monksdream

Monksdream 2年前

glenn1919

glenn1919 2年前

IFRX................................https://stockcharts.com/h-sc/ui?s=IFRX&p=W&b=5&g=0&id=p86431144783

Monksdream

Monksdream 2年前

Monksdream

Monksdream 3年前

IFRX new 52 week low

TheFinalCD

TheFinalCD 3年前

https://finviz.com/quote.ashx?t=IFRX&ty=c&ta=1&p=d

does have a REGISTERED SHELF OFFERING

https://dilutiontracker.com/app/search/IFRX?a=dbb88c

Apr-05-23 Upgrade Guggenheim Neutral ? Buy $8

enthalpy

enthalpy 3年前

True waiting on that skin cancer p2 data release or EUA sales update.

peterus

peterus 3年前

going the wronge way

peterus

peterus 3年前

yup $10+ coming

enthalpy

enthalpy 3年前

I added more and its a decent position. I think we have a shot at 10 to 15 short term. Friday looked promising. Hopefully we get a second wave to start in 2 weeks.

peterus

peterus 3年前

you still in ????
im still holding 4s

Gator44

Gator44 3年前

Closing of offering, here comes first stop $6.25

frans

IFRX should go slowly 5$ +

frans

IFRX 4.2 now slowly on the move

frans

in here at 4.10

the_stockoracle

the_stockoracle 3年前

Still in downtrend and they will keep diluting

enthalpy

enthalpy 3年前

I bought more 4.04

Gator44

Gator44 3年前

Couple of pennies are cloce enough

the_stockoracle

the_stockoracle 3年前

Learn your charts lol $3.93 is the gap fill

Gator44

Gator44 3年前

Gap filled boys and girls...
Big boy buying today !!!

Tidal Trust II Defiance ...

Vencanna Ventures

Bond 2.50 Pb S544 11-27 /z

Kobe Bussan (PK)

Xtrackers MSCI AC World ...

Fictor Alimentos ON

Ubs Ag London Branch Aut...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。